Kura Oncology adopts 2023 Inducement Option Plan reserving 600,000 shares for new hires

Kura Oncology, Inc.

Plan reserves 600,000 shares of common stock for nonstatutory stock option grants to new employees as inducement material to employment.
Awards must be approved by a majority of independent directors or independent compensation committee per Nasdaq Rule 5635(c)(4).
Plan terms are substantially similar to the company's stockholder-approved Amended and Restated 2014 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.